A 90-day oral (dietary) toxicity study of the 2R,4R-isomer of monatin salt in Sprague–Dawley rats |
| |
Authors: | J Hlywka WA Brathwaite MO Rihner AI Nikiforov AK Eapen |
| |
Institution: | aCargill, Inc.,15407 McGinty Road West, Wayzata, MN 55391, USA;bToxicology Regulatory Services, Charlottesville, VA, USA;cWIL Research Laboratories, Ashland, OH, USA |
| |
Abstract: | The root bark of Sclerochitin ilicifolius contains an intensely sweet substance analytically identified as isomers of 2-hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid and generically coined “monatin.” Groups of male and female Crl:CD(SD) rats were fed 0 (control), 5000, 10,000, 20,000 or 35,000 ppm R,R-monatin salt in the diet for 90 days. There were no toxicologically relevant clinical or histopathological findings in any of the test article-treated groups. Significantly lower cumulative body weight gains were noted in the 35,000 ppm group. Mean body weights in the 35,000 ppm group males and females were 7% and 12% lower, respectively, than the control group at study week 13. In the absence of other observations associated with systemic toxicity and lower food consumption, the magnitude of the body weight difference in the 35,000 ppm group females relative to the control group exceeded 10%, which indicated attainment of a maximum tolerated dose (MTD) level. Based on the results of this study, and conservatively assuming the body weight observations at the MTD to be indicative of an adverse effect, the dietary no-observed-adverse-effect level (NOAEL) of R,R-monatin salt for 90 days was 20,000 ppm in female rats (approximately 1544 mg/kg bw/day) and 35,000 ppm in male rats (approximately 2368 mg/kg bw/day). |
| |
Keywords: | Abbreviations: ANOVA analysis of variance APTT activated partial thromboplastin time FDA United States Food and Drug Administration FOB functional observational battery HDW hemoglobin distribution width MCH mean corpuscular hemoglobin MCHC mean corpuscular hemoglobin concentration MCV mean corpuscular volume MTD maximum tolerated dose NOAEL no-observed-adverse-effect level OECD Organisation for Economic Cooperation and Development PT prothrombin time RANOVA repeated measures of analysis of variance RDW red cell distribution width |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|